Zymeworks Inc ZYME

Healthcare Biotechnology

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

NDAQ:ZYME - Post by User

Zymeworks Inc

<< Previous

Bullboard Posts

Next >>

Post by Oneinamillionon Apr 29, 2022 10:47am

148 Views

Post# 34642256

All Blue Falcons holdings

According to one website ABF owns over 3M shares of Zymeworks already....so if that is true it would seem to make sense for them to make this kind of offer. My guess is that the board will try to hold out for more as this Z is at a low point re share price right now. All imho.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in